We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Focus on Ophthalmology

Due to advances in our understanding of disease biology, the chance to make a significant difference in the lives of people with ocular disorders has never been greater.

We’re currently focused on diseases of the eye that cause significant vision loss such as wet age-related macular degeneration, geographic atrophy, diabetic macular edema and glaucoma.

Our scientists continue to investigate new targets, bringing a wide range of therapeutic platforms to bear, such as agonist antibodies that can enhance pathways to reverse the course of disease. Always keeping the needs of the patient in mind, we’re also evaluating proprietary technologies for sustained drug delivery through ocular implants, as well as innovative formulations and biodegradable implants. Genentech’s pursuit of personalized therapies extends to the ophthalmology space, where we are looking at specific biomarkers and genetic modifiers.

By leveraging previous research conducted in our immunology, vascular biology and neurobiology groups, and applying it to pathologic conditions of the eye, we hope to shed new light and further our progress in understanding and treating ophthalmic diseases.

Key Publications

Journal of Experimental Medicine, January 2016
IL-33 amplifies an innate immune response in the degenerating retina
Nature, March 2015
MAP4K4 regulates integrin-FERM binding to control endothelial cell motility
The Journal of Pathology, January 2014
Mechanisms of age-related macular degeneration and therapeutic opportunities
Ophthalmology, January 2014
Geographic Atrophy: Clinical Features and Potential Therapeutic Approaches
The Journal of Cell Biology, September 2013
JNK-mediated phosphorylation of DLK suppresses its ubiquitination to promote neuronal apoptosis
Investigate Ophthalmology & Visual Science, September 2012
Activation of the Alternative Complement Pathway in Vitreous is Controlled by Genetics in Age-Related Macular Degeneration
Cell, October 2009
TSPAN12 Regulates Retinal Vascular Development by Promoting Norrin- but Not Wnt-Induced FZD4/β-Catenin Signaling